Nuvation Bio Inc.
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $62.9M
- Net income
- -$204.6M
- Total assets
- $594.8M
- Market cap
- $1.7B
- Operating margin
- -338.7%
- Net margin
- -325.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $62.9M
- Operating expenses
- $276.0M
- Operating income
- -$213.1M
- Income tax
- $0
- Net income
- -$204.6M
- EPS (basic)
- $-0.60
- EPS (diluted)
- $-0.60
Balance sheet
- Total assets
- $594.8M
- Current assets
- $571.5M
- Total liabilities
- $289.1M
- Current liabilities
- $82.2M
- Shareholders’ equity
- $305.7M
Cash flow
- Operating cash flow
- -$173.4M
- Investing cash flow
- $99.5M
- Financing cash flow
- $202.5M
- Net cash flow
- $128.4M
Statements via Polygon.io (SEC filings)
- Market cap
- $1.7B
- EPS (diluted)
- $-0.6
- Shares outstanding
- 349.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 10, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $204.6M in FY2025.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nuvation Bio Inc..
Write a review
News about Nuvation Bio Inc.
News & sentiment via Polygon.io
